/

Immunology and Infection

/

Production of Human CRISPR-Engineered CAR-T Cells

JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Immunology and Infection

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

11,767 Views

•

06:33 min

•

March 15, 2021

DOI:

10.3791/62299-v

DOI:

10.3791/62299-v

•

06:33 min

March 15, 2021

•

33 Views

Sangya Agarwal*^1,2, Nils Wellhausen*^1,2, Bruce L. Levine^1,2, Carl H. June^1,2

¹Center for Cellular Immunotherapies, Perelman School of Medicine,University of Pennsylvania, ²Parker Institute for Cancer Immunotherapy,University of Pennsylvania

Summary

Here, we present a protocol for gene editing in primary human T cells using CRISPR Cas Technology to modify CAR-T cells.

Explore More Videos

CRISPR-Cas9 CAR T Cell Therapy Genome Editing Human Clinical Trials PBMC CD4 T Cells CD8 T Cells IL-7 IL-15 Ribonucleoprotein (RNP) Complex Electroporation T-cell Activation And Expansion Sequencing Primers

Read Article